433 results about "Hyperglycemias" patented technology

Disclosed are methods of improving treatment adherence and compliance after discontinuation of incretin-based therapies, such as GLP-1 and / or GIP agonists, using pharmacotherapies comprising the disclosed therapeutic compounds and combinations. In some aspects, methods include treatment of psychological factors affecting other medical conditions (PFAOMC) following the administration of incretin-based therapies to treat obesity or hyperglycemia, and related disorders. In some aspects, disclosed pharmacotherapies for use in the methods include agents that modulate monoaminergic neurotransmission, administered alone or together, such as in disclosed combinations having advantageous synergistic effects.

The invention relates to the technical field of medical information processing, in particular to a method for constructing a model for predicting the onset risk of hyperglycemia-related ovarian cancer, which comprises the following steps of: performing isolated analysis on the blood glucose level of a patient during each physical examination, and calculating the blood glucose abnormality of the patient during each physical examination in combination with the local trend characteristics of the blood glucose level, so as to determine the onset risk of hyperglycemia-related ovarian cancer; analyzing the difference between the blood glucose value of the patient and the overall trend information, and evaluating the abnormal blood glucose condition in combination with the abnormal blood glucose degree of the patient; the prediction credibility of the blood glucose value of the patient during each physical examination is calculated by utilizing the incidence relation between the blood glucose value and the tumor marker concentration in different periods and combining the evaluation result of the abnormal blood glucose condition of the patient during each physical examination; therefore, the blood sugar value data is subjected to data cleaning so as to further predict the onset risk of the hyperglycemia-related ovarian cancer of the patient. According to the method, the prediction accuracy of the onset risk of the hyperglycemia-related ovarian cancer is effectively improved.

The invention discloses a hexapeptide with a hypoglycemic effect as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The amino acid sequence of the hexapeptide is Ile-Trp-Asp-Pro-His-Phe, and the amino acid sequence of the hexapeptide is as shown in the specification. The novel hexapeptide IWDPHF with prominent DPP-IV inhibition ability is successfully identified from mulberry leaf proteolysis products through liquid chromatography-mass spectrometry and a virtual screening method, the hexapeptide IWDPHF shows the blood glucose reducing effect superior to that of part of known peptides in an in-vitro enzyme activity inhibition experiment and a zebra fish hyperglycemia model, and no obvious side effect exists; the compound has a good potential of being developed into a hypoglycemic functional product or a drug lead compound. The invention further provides the mulberry leaf peptide with the peptide fragment IWDPHF, and the mulberry leaf peptide can be applied to preparation of drugs or food for reducing blood sugar. The invention provides a new scheme and theoretical basis for treatment of diabetes, and has good market prospect and application potential.

The invention discloses a preparation method and application of a glucose sensor based on an acupuncture needle, the sensor is prepared based on a specific structural design and a molecular recognition mechanism by taking the acupuncture needle as a substrate, and high-specificity and high-sensitivity detection of glucose concentration is realized through drain current change. According to the present invention, the biosensor has the ultra-wide dynamic detection range (0-40 mmol.L <-1 >), covers the clinical range from hypoglycemia to severe hyperglycemia, has the low detection limit of 54 mol.L <-1 >, has excellent grid regulation and control ability, shows the significant on-off ratio and the rapid response characteristic during the detection process, and meets the requirements of the biosensor on sensitivity and real-time performance; and the device has quick response capability to grid voltage change, so that the device has good stability and repeatability under repeated operation, and a direction and a basis can be provided for the development of a blood glucose monitoring technology with continuous, real-time and accurate characteristics.

The invention relates to a pharmaceutical composition. The pharmaceutical composition comprises a PCSK9 inhibitor and a GLP-1 receptor agonist, the invention also relates to application of the medicine composition in preparation of medicines for treating hyperglycemia, diabetes, obesity and / or cholesterol-related diseases.

The invention provides a fructus cannabis protein peptide capable of reducing blood sugar and regulating glycometabolism and a preparation method and application thereof, and belongs to the technical field of functional active peptides, and the preparation method comprises the following steps: performing low-temperature supersonic fluid crushing on fructus cannabis, performing enzymolysis pretreatment on the crushed fructus cannabis, adding compound protease for enzymolysis, adding PNGaseF enzyme for further enzymolysis, and performing freeze drying to obtain the fructus cannabis protein peptide capable of reducing blood sugar and regulating glycometabolism. And carrying out membrane ultrafiltration interception and enrichment on the enzymolysis supernatant, carrying out tangential flow filtration, concentrating, drying and sterilizing to obtain the fructus cannabis protein peptide. Tests prove that the novel fructus cannabis protein peptide has the following remarkable effects that the fasting blood glucose level can be remarkably reduced, and uncomfortable symptoms such as thirst, polydipsia, diuresis and weakness caused by hyperglycemia are relieved; the symptoms of glucose intolerance and insulin resistance caused by hyperglycemia can be obviously relieved, and the onset risk of type 2 diabetes mellitus is reduced; the level of fasting serum insulin and glycosylated hemoglobin can be obviously reduced, and the level of serum GLP-1 can be improved.

The invention relates to the technical field of RNA interference, and particularly discloses an RNA interference fragment of a crustacean hyperglycemia hormone gene and application of the RNA interference fragment. The RNA interference fragment provided by the invention is injected into a third step foot of a river crab in an injection manner and is used for interfering the mRNA expression quantity of a hyperglycemia hormone gene CHH of a crustacean of the river crab. The fighting behavior of the eriocheir sinensis is effectively controlled, the yield in large-scale breeding of the eriocheir sinensis is improved, and economic losses caused by incomplete crabs due to fighting of the eriocheir sinensis are reduced.

A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and / or a detected location of the user.

Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.

The invention discloses a glucose-responsive hydrogen sulfide release cascade nano-enzyme as well as a preparation method and application thereof. The cascaded nano-enzyme takes BSA as a growth template and a carrier, and FeS and Au nano-particles are loaded. The FeS-coated Au is synthesized by adopting a biomineralization method, so that the co-loading of FeS and Au is realized, and good biocompatibility is achieved. Meanwhile, by combining the peroxidase-like activity of FeS and the glucose oxidase-like activity of Au, glucose can be catalyzed in a cascade manner to generate toxic hydroxyl free radicals, and drug-resistant bacteria are efficiently killed. In addition, the FeS (at) Au cascade nano-enzyme has a hydrogen sulfide gas release function, and can promote vascular regeneration by up-regulating a hypoxia inducible factor-1 pathway. The cascade nano-enzyme responding to the hyperglycemia microenvironment is combined with a gas treatment mechanism, blood glucose can be effectively consumed, drug-resistant bacterium infection can be eliminated, revascularization can be promoted, and a new strategy is provided for treatment of diabetes wounds infected by drug-resistant bacteria and regeneration of skin tissues.

Diabetes is a disease characterized by high levels of blood glucose. It is important to keep diabetes under control to avoid short- and long-term complications. Diabetes can affect vision due to the alterations it produces in the blood vessels of the retina. This is known as Diabetic Retinopathy (DR), which is one of the leading causes of impaired vision in developed countries. One of the complications of diabetic retinopathy is Diabetic Macular Edema (DME), which is the leading cause of vision loss in diabetic patients and can appear at any stage of diabetic retinopathy. This consists of the gradual accumulation of fluid in the macula, the most important area of the retina. The determination of diabetic macular oedema is very important for the retina. The determination of diabetic macular oedema is very important for adequate treatment of this condition. A variety of technological options are used for detecting diabetic retinopathy, although only the most sophisticated detect macular oedema, a complication that appears as a consequence of diabetic retinopathy and is one of the leading causes of blindness. The invention describes a portable system for detecting diabetic macular oedema by capturing a fundus image using a portable ophthalmoscope; said image is sent via wired or wireless means to an embedded system that has an algorithm based on artificial intelligence, which extracts information from the image and processes same to identify the presence of the condition being studied.

The invention discloses a non-invasive hyperglycemia detection method based on a multi-modal physiological signal, and the method comprises the steps: obtaining the multi-modal physiological signal of a person to be detected, the multi-modal physiological signal comprising a BVP signal, an HR signal and an EDA signal; extracting time domain features and frequency domain features of the BVP signal, the HR signal and the EDA signal through three-stage discrete wavelet transform, extracting DNN features of the BVP signal, the HR signal and the EDA signal through a preset CNN-LSTM network, and fusing the time domain features, the frequency domain features and the DNN features by using a deep neural network to obtain a mixed feature vector; and inputting the time domain features, the frequency domain features, the DNN features and the mixed feature vectors of the BVP signal, the HR signal and the EDA signal into a pre-trained integrated learning model, and predicting whether the to-be-detected person is in a high glucose state. The method has the advantages of noninvasiveness, high precision, real-time performance and individuation, is suitable for continuous monitoring and early screening of prediabetic people, and has good clinical prospects and practical application values.

Incretin analogs are provided that have activity at each of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and obesity.

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

The invention belongs to the field of food processing, and particularly relates to rice starch ester as well as a preparation method and application thereof. According to the invention, by exploring the action rule of reaction time, reaction temperature, pH value and acid addition amount on modified rice starch ester, the content of resistant starch in rice starch is increased and the GI value is reduced through esterification modification, so that the rice starch with the function of regulating blood sugar level is obtained; the product also can significantly improve inflammation and fat accumulation symptoms caused by hyperglycemia; in a diet intervention experiment, both the CRS and the MRS show an effective reduction effect on the weight growth rate, the blood sugar level, the visceral organ index and the inflammatory factor content of the hyperglycemia mouse. The result shows that the CA / MA rice starch ester not only has the function of regulating the blood sugar level, but also can remarkably improve inflammation and fat accumulation symptoms caused by hyperglycemia, and has a positive effect on maintaining the overall health.

The invention discloses a glucose responsive composite material as well as a preparation method and application thereof. The composite material sequentially comprises porous metal, a polydopamine layer and a mesoporous silicon dioxide coating from inside to outside, the porous metal is coated with the polydopamine layer, the polydopamine layer is coated with the mesoporous silicon dioxide coating, and preparation raw materials of the mesoporous silicon dioxide coating comprise aminated mesoporous silicon dioxide, aspirin, 4-carboxyphenylboronic acid and sodium alginate. The composite material disclosed by the invention has blood sugar concentration dual-mode response capability, aspirin is suddenly released in a hyperglycemia environment, up-regulation expression of anti-inflammatory factors is remarkably promoted, and an anti-inflammatory effect is dominated; in a normal blood glucose environment, aspirin is slowly released, and the expression of osteogenic factors is remarkably up-regulated, so that osteogenic differentiation is promoted as a leading effect; the dual-mode response realizes accurate regulation and control of ASP dosage, organically combines bone formation promotion and anti-inflammatory functions, and provides a brand new solution for patients with bone defects, especially patients with bone defects caused by diabetes mellitus.

The present invention discloses modified-release bilayer tablets consisting of two layers, layer 1 consisting 500 mg sustained release metformin and layer 2 consisting 250 mg normal release metformin and 5mg / 10mg delayed-release dapagliflozin. This formulation is meticulously designed to regulate blood glucose levels effectively over an extended period. Immediate-release metformin swiftly addresses acute glucose spikes, while sustained-release metformin ensures prolonged glucose control, minimizing fluctuations throughout the day. The delayed-release dapagliflozin component allows for controlled and timed release, managing persistent hyperglycemia synergistically with metformin. By optimizing efficacy and minimizing glucose fluctuations, this innovative formulation offers a promising solution for stable glycemic control in individuals with diabetes. Present invention aims to improve patient outcomes and enhance overall quality of life by maintaining stable glucose levels and reducing the risk of complications associated with uncontrolled diabetes.

The invention relates to the technical field of polypeptide drugs for metabolic diseases, in particular to a glucagon-like peptide (GLP-1), a glucose-dependent insulinotropic polypeptide (GIP) and a glucagon (GCG) triple receptor agonist (protein). According to the triple receptor agonist protein provided by the technical scheme, weight reduction is achieved, meanwhile, lower side effects are shown, and drug compliance is enhanced. The triple receptor stimulant researched and developed by the technical scheme can be applied to preparation of medicines with the effects of losing weight, reducing lipid or reducing blood sugar, solves the technical problem that the existing GLP-1, GIP and GCG triple receptor stimulants are difficult to reduce side effects while reducing body weight, and breaks through the weight loss mode that the traditional medicines depend on appetite suppression; due to the unique action mechanism and good safety, a safer and more effective treatment scheme is provided for patients, and the medicine has wide market prospects and social benefits.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

The invention discloses an agaric polypeptide VR5 with alpha-glucosidase inhibitory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the auricularia auricula polypeptide VR5 is VGMLR, and the auricularia auricula polypeptide VR5 can be prepared by a solid-phase synthesis method and an enzymolysis method (flavourzyme). The agaric polypeptide VR5 has the beneficial effects that experiments prove that the agaric polypeptide VR5 has very high alpha-glucosidase inhibitory activity, IC50 is equal to 34.96 mu g / mL, the agaric polypeptide VR5 can be used as an alpha-glucosidase inhibitor for preventing or treating alpha-glucosidase mediated diseases, and the agaric polypeptide VR5 can be used for preventing or treating alpha-glucosidase mediated diseases. Or as a hypoglycemic active component, the composition is added into auxiliary hypoglycemic functional food for auxiliary regulation of the blood sugar level of hyperglycemia people.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating glycolipid metabolic diseases and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15-19 parts of coptis chinensis, 10-15 parts of rhodiola rosea, 10-20 parts of gynostemma pentaphylla, 9-12 parts of kapok, 10-15 parts of soapberry, 9-15 parts of salvia miltiorrhiza, 10-15 parts of rhizoma alismatis, 9-12 parts of oriental wormwood, 9-12 parts of radix bupleuri, 5-10 parts of semen cassiae, 10-15 parts of rhizoma anemarrhenae, 10-15 parts of hawthorn, 6-9 parts of polygonum cuspidatum and 5-10 parts of fructus aurantii. The traditional Chinese medicine composition disclosed by the invention has the effects of inhibiting hyperlipidemia, hyperglycemia and hepatic lipid accumulation and relieving insulin resistance, and has a remarkable curative effect on relieving and treating glycolipid metabolic diseases.

The invention relates to the technical field of non-invasive monitoring, in particular to a diabetes blood glucose fluctuation trend prediction method based on foot temperature and humidity change, which comprises the following steps: continuously collecting temperature, humidity and motion data of multiple areas of a foot through a foot wearable device, extracting a feature set related to blood glucose fluctuation from the preprocessed data, and calculating the blood glucose fluctuation trend according to the feature set; and fusing the feature set and context event information, inputting the fused feature set and context event information into a multi-task deep learning prediction model, visually displaying a prediction result in the forms of a trend arrow, a probability interval and a risk level, and triggering early warning in advance when a hyperglycemia or hypoglycemia event is predicted to be about to occur. The method is completely noninvasive and high in compliance, prospective trend prediction can be carried out based on existing diabetic foot monitoring wearable equipment, individual physiological characteristics of a user can be continuously learned through a built-in personalized self-adaptive mechanism, dynamic calibration is carried out on the model through incremental learning, and the prediction accuracy is improved. And the prediction precision is continuously improved along with the use time.

A system, method and non-transient computer readable medium for assessing the opportunity to address either hyperglycemic or hypoglycemic risk (or both) in patients with diabetes based on historical continuous glucose monitoring (CGM) data.

The invention discloses a formula of a composition capable of assisting in reducing blood sugar and preventing diabetes, and relates to the field of health food, the composition has the effects of reducing blood sugar and preventing diabetes, and the composition comprises the following composition components: 0.25 to 0.37% of bitter gourd peptide, 0.018 to 0.026% of corosolic acid, 0.39 to 0.48% of mulberry leaf extract, 0.083 to 0.095% of pseudo-ginseng extract, 0.115 to 0.132% of radix polygonati officinalis extract, and 0.00003 to 0.00005% of chromium-enriched yeast. By adopting the composition formula for assisting in reducing blood sugar and preventing diabetes, the formula composition has the effects of assisting in reducing the blood sugar level and treating. Meanwhile, the composition also has a synergistic effect on prevention of diabetes caused by hyperglycemia symptoms, the components of the composition are equal-part compositions formed by physical stirring and uniform mixing, and the increase of postprandial blood sugar level can be effectively inhibited, so that the effects of assisting beta cells of a body to secrete insulin and improving the blood sugar level are achieved. And insulin can promote the utilization of sugar by cells, the synthesis of hepatic glycogen and the improvement of the metabolism of sugar, so that the effect of reducing blood sugar is finally achieved. The raw materials of the composition can be purchased and obtained in the market, the raw materials are simple and easy to obtain, the production benefit is high, and the composition is suitable for being widely used.

The invention relates to the technical field of medical instruments, and discloses a dynamic blood glucose monitoring system after kidney transplantation based on artificial intelligence, the system comprises a data acquisition and transmission module, an AI decision support module, a risk early warning and report generation module, a feedback and optimization module and a system integration module; an AI drug disturbance analysis module is arranged, when postoperation blood glucose is monitored in real time, an immunosuppressor-blood glucose dynamic response model is established, the causal relationship between the blood concentration of a specific drug and glucose metabolism is analyzed, and a drug correlation event label is labeled in real time; by means of the method, whether blood glucose fluctuation is triggered by immunosuppressor metabolism abnormality or not can be accurately recognized, it is avoided that drug-induced hyperglycemia is misjudged as an dietary event, the accuracy of treatment intervention decision making is guaranteed, and the rejection risk is reduced.

The invention belongs to the field of functional food, health care products and medicines, and particularly relates to okra polysaccharide with a function of improving metabolic syndrome as well as a preparation method and application of the okra polysaccharide. The preparation method of the okra polysaccharide comprises the steps of pretreatment, alcohol soaking of raw materials, extraction of filtrate, alcohol precipitation, dialysis, concentration and freeze drying. The okra polysaccharide provided by the invention can improve metabolic syndrome indexes including obesity, hyperlipidemia, hyperglycemia, hypertension, liver inflammation, flora disorder and the like, the comprehensive improvement effect is better than that of commercial apple pectin, citrus pectin and inulin, and the okra polysaccharide can be used as prebiotics to enrich intestinal beneficial bacteria deficiency caused by metabolic syndrome. The sources of natural medicines and health-care products for preventing and treating the metabolic syndrome are widened.

The invention provides a recognition and early warning method and device for irritable hyperglycemia, electronic equipment and a storage medium, and is applied to the technical field of medical data processing. According to the method, data type information (including FreeStyle LibreH dynamic blood glucose and glycosylated hemoglobin data), influence factor data (improved and preset irritable hyperglycemia index and the like) and abnormal state information (fasting interference and detection difference) are taken; acute-stage and chronic-stage average blood glucose basic data are generated through preprocessing. The index weight is enhanced and improved by means of a dynamic fusion engine, the probability is predicted by combining space-time correlation analysis and binary logistic regression, and the abnormal characteristics are obtained by comparing the difference of the AUC by adopting Delog test. The multi-modal features are processed to obtain an identification result, clinical indexes screened by LASSO are fused, index differences are compared to generate risk influence factors, finally, a dynamic early warning result is generated based on a space-time correlation early warning engine and a multi-target strategy, and accurate identification and early warning are achieved.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

The invention belongs to the technical field of medicines, and particularly provides a novel application of a theaflavin compound in preparation of a product for inhibiting dipeptidyl peptidase-4 (DPP-4), and the theaflavin compound is one or more of theaflavin-3-gallate (TF2A), theaflavin-3 '-digallate (TF3) and theaflavin (TF). The research systematically proves that TF2A, TF3 and TF have new application of inhibiting DPP-4 for the first time: in-vitro enzymology and fluorescence experiments show that theaflavin can inhibit DPP-4 and interact with DPP-4, and molecular docking further shows possible binding configuration and key action sites of theaflavin. In vivo, the activity of DPP-4 in serum and different tissues of high-fat diet mice can be reduced, serum glucagon-like peptide-1 (GLP-1) can be up-regulated, and glycometabolism and inflammatory phenotype can be improved. Therefore, the theaflavin compound disclosed by the invention can be applied to preparation of products for inhibiting DPP-4, and has a good development prospect.

Provided herein are methods for treating obesity or diabetes by administering a 15- PGDH inhibitor to a subject. In some cases, the methods provided herein additionally involve administering to a subject an agent selected from the group consisting of: a glucagon- like peptide- 1 (GLP-1) receptor agonist, a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, a glucagon receptor agonist, a GLP-1 receptor / GIP receptor co- agonist, a GLP-1 receptor agonist / GIP receptor antagonist, a GLP-1 receptor / glucagon receptor co-agonist, a GLP-1 receptor / GIP receptor / glucagon receptor triple agonist, a GLP-1 receptor / GLP-2 receptor co-agonist, a combination of a GLP-1 receptor agonist and an amylin receptor agonist.